ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay

July 17, 2009

12 Minority CCOPs Awardees Names, San Antonio Gets 2

September 21, 1990

Anna Barker Named Deputy Director for Strategic Scientific Initiatives

December 6, 2002

Bill Introduced To Ban Smoking From All Flights

March 24, 1989

Also in this 8-page issue: The Cancer Letter wins two awards for its “authoritative examination” of NCI.

June 11, 2004

NAS Honors David Kessler; Satcher Seeks Obesity Plan.

January 12, 2001